Understand · Wellness
The short answer on peptides after breast cancer
"Peptide" describes a type of molecule. It tells you nothing about whether something is safe. Some peptides are well-tested prescription drugs, including hormone treatments used in breast cancer care. The injectable "wellness" peptides sold online and in clinics are a different matter: none is FDA-approved, there's little human research on them, and nobody knows how they affect cancer cells. If you've had breast cancer, talk to your oncology team before you try one.
What to know about peptides after breast cancer
- Same word, very different things. Insulin, GLP-1 weight-loss drugs and some breast cancer hormone treatments are peptides. So is a vial of BPC-157 bought online.
- Wellness peptides aren't approved drugs. FDA scientists say there's little data showing they can be used safely, and products sold under the same name can contain different things.
- The cancer question is unanswered. A breast oncologist at Memorial Sloan Kettering says it's unknown how these compounds affect cancer cells.
- GLP-1 drugs are a separate conversation. Early research in women with breast cancer looks interesting but isn't conclusive, and the FDA warns against unapproved and "research only" versions.
- Peptide cancer treatments are real, and mostly early. A few are standard care; most of what's in the headlines is still in the lab or in trials.
What is a peptide?
A peptide is a short chain of amino acids, the building blocks of protein. Memorial Sloan Kettering (MSK) explains that peptides generally have up to about 50 amino acids, while proteins usually have several hundred. Both work as chemical messengers that help tell cells what to do.
Many familiar medicines are peptides. MSK lists insulin, growth hormones, GLP-1 drugs such as semaglutide (Ozempic, Wegovy), and hormone-blocking medicines used for hormone-driven breast and prostate cancers. If you've had injections to shut down your ovaries during breast cancer treatment, you may already have taken one. The National Cancer Institute describes goserelin (Zoladex) and leuprolide (Lupron) as lab-made versions of a natural peptide hormone. They are used to suppress the ovaries, which, NCI explains, make most of a woman's estrogen before menopause.
So "peptide" is a chemistry word, the way "protein" or "fat" is. Hearing that something is a peptide, or "natural," tells you nothing about whether it's safe or whether it works.
What are the "wellness" peptides people are injecting, such as BPC-157?
These are the ones in your feed: BPC-157, TB-500, GHK-Cu, KPV, MOTS-c and others, usually sold as injections, sometimes as nasal sprays, creams or powders. MSK says they're promoted for immunity, energy, muscle recovery, inflammation, wound healing and stress. MSK breast oncologist Dr. Larry Norton says those claims lack strong evidence, and that proving them would take lab work and controlled clinical trials long enough to catch long-term side effects.
None of these is an FDA-approved drug. Many are bought online labeled "for research use only" or "not for human consumption," as NPR has reported. MSK notes that little is known about how they're made, stored and shipped, that they can break down in transit, and that they may contain harmful impurities.
Where the FDA stands. This is moving quickly. In 2023 the FDA put BPC-157 and TB-500 on its list of substances that may pose significant safety risks when compounding pharmacies (pharmacies that mix custom medicines) make them, the Associated Press reports. The FDA's review of these peptides flagged the risk of immune reactions from impurities or clumping, problems confirming what's actually in the product, and little or no human safety data. Earlier this year, Health Secretary Robert F. Kennedy Jr. announced they would come off that list, and in July an FDA advisory panel narrowly voted to recommend letting pharmacies compound six of them, including BPC-157, TB-500 and KPV. The panel's votes aren't binding. As of MSK's September 2026 article, the FDA had not made a final decision.
What the panel heard is worth knowing. According to the AP, FDA scientists said the five BPC-157 studies they reviewed were short and small, and they found no human studies of TB-500. NPR reports that FDA officials said products sold under the same peptide name can vary considerably in what they contain, and that the FDA's review raised the possibility that peptides could encourage cancer growth. As Dr. Norton points out, being allowed to compound a substance is not the same as FDA approval based on clinical trials.
Are wellness peptides risky after breast cancer?
The honest answer is that nobody knows, and that's the problem. We found no human studies of wellness peptides in people who have had breast cancer.
Dr. Norton says it is unknown how these compounds affect cancer cells, and that the same healing or anti-inflammatory effects people want from them could possibly influence how tumors grow. That's a theoretical concern, not a proven harm. But a product sold to make tissue grow and repair faster deserves a hard look after cancer. The FDA's own safety notes on some peptides point the same way: for one (LL-37), animal and lab findings suggested it might promote tumors in some tissues; for another, sold as a tanning peptide (melanotan II), there are published case reports of melanoma. Neither proves anything about other peptides, but both show why "unknown" isn't the same as "fine."
We also found no research on how wellness peptides interact with tamoxifen, aromatase inhibitors, ovarian suppression or targeted drugs. And MSK raises a quieter risk: using peptides to treat symptoms of something serious can delay finding out what's actually wrong. After breast cancer, a new ache or a fatigue that won't lift should go to your care team first.
The everyday risks apply too. AP reports that medical experts warn of infection and allergic reactions from unregulated products.
If what's driving you is joint pain from an aromatase inhibitor, poor sleep or slow recovery, those are real problems, and MSK's advice is to bring them to your care team rather than buying untested products online. MSK, for example, has an integrative medicine service offering acupuncture, herbal medicine and mind-body therapies; ask whether your cancer center has something similar.
Are GLP-1 weight-loss drugs and collagen peptides safe after breast cancer?
GLP-1 drugs. Semaglutide and tirzepatide (Mounjaro) are peptides, and the FDA-approved versions have been through clinical trials. Whether they're right for you after breast cancer is a question for your oncology team, and research is just starting to address it. Breastcancer.org summarized studies presented at a major breast cancer meeting that linked GLP-1 use to lower breast cancer risk, fewer treatment side effects and better survival in some groups. It stresses that all of them looked back at health records. They can show links but not cause and effect, and nearly all involved people with obesity, diabetes or both. Its advice: discuss it with your oncology team.
Where you get it matters. The FDA does not review compounded or unapproved GLP-1 drugs for safety, effectiveness or quality before they're sold. It has warned companies selling semaglutide, tirzepatide and similar drugs labeled "for research purposes" or "not for human consumption," and it urges people not to buy them. It has also received reports of hospitalizations tied to dosing errors with compounded semaglutide. Because these drugs slow how fast the stomach empties, ask your pharmacist whether that matters for any pills you take.
Collagen peptides. The powders in your coffee are sold as dietary supplements, which the FDA doesn't review for safety or effectiveness before sale. Harvard's School of Public Health says a few small trials suggest collagen may help skin elasticity and joint pain, but human research is limited and nearly all of it is funded by the industry or by authors with industry ties. It also notes concern about heavy metals in some products. We found no research on collagen supplements specifically after breast cancer, so mention them to your team like any other supplement.
Which peptide-based breast cancer treatments are real, and which are still in research?
Some of this is already routine. Goserelin and leuprolide, the ovarian suppression drugs above, are peptide medicines used in breast cancer care today.
Researchers are also testing peptides as vaccines. NCI's drug dictionary describes one, nelipepimut-S, as a peptide vaccine built from a piece of the HER2 protein, meant to train the immune system to go after HER2-positive cancer cells. It has been studied in NCI-sponsored trials, but it is not an approved treatment. NCI says vaccines built from shared tumor antigens are still experimental, and its list of approved cancer treatment vaccines doesn't include one for breast cancer.
The headlines about peptide "nanomedicine" are earlier still. A 2023 review in the journal Nanomaterials looked at small peptides that latch onto HER2 and could, in theory, carry chemotherapy or imaging agents straight to tumor cells. The studies it describes were done in cells, in animals or on computers; none had reached people. Another 2023 review, in Frontiers in Pharmacology, covered ways peptides might help breast cancer cells stop resisting chemotherapy. Its authors say most of the experiments so far were in lab dishes, with almost no animal studies, and that peptides face practical hurdles: they're costly to make, break down quickly in the body and can trigger immune reactions.
That's what research looks like years before it becomes treatment. If you're interested in a trial for your type of breast cancer, ask your oncologist, search NCI's clinical trials listings at cancer.gov, or call NCI at 1-800-4-CANCER (1-800-422-6237).
How do you talk to your cancer care team about peptides?
Plainly. Your team can only help with what they know about.
Tell them everything. Prescriptions, supplements, powders, creams and anything you inject, including what a med spa, wellness clinic or telehealth service gave you.
Bring the label. A photo of the vial, box or website listing helps, since peptide names don't reliably tell anyone what's inside.
Say what you're hoping it will fix. If it's pain, sleep, energy, weight or skin, there may be tested options, and the symptom itself may need checking.
Ask before scans and labs. Let your team know what you're taking before blood work or imaging, so they can tell you whether it matters.
If you've been feeling unlike yourself since treatment ended, this is worth reading too.
When to call your care team about a peptide, supplement or injection
- Redness, warmth, swelling, pus or growing pain where you injected something
- Fever or chills after an injection
- Hives, itching, a rash or swelling after starting any new product
- Any new or unexplained symptom after starting a peptide, supplement or weight-loss drug
Trouble breathing, swelling of the face, lips or throat, chest pain, or feeling faint can be signs of a severe reaction. Call 911.
Questions to ask your care team about peptides
- Is it safe for me to take this with my hormone therapy or other cancer medicines?
- Is there any reason to think this could affect my risk of cancer coming back?
- Could it change my blood work or scans?
- Is there a tested treatment for the problem I'm trying to fix?
- Would a GLP-1 drug make sense for me, and how would you want to monitor it?
- Are there trials of peptide-based treatments or vaccines for my type of breast cancer?
- Does our cancer center have an integrative medicine service I could see?
Sources: Memorial Sloan Kettering Cancer Center, Reality Check: What You Should Know About Peptides and Cancer (September 3, 2026); FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (April 2026) and FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (October 1, 2026); Federal Register, Pharmacy Compounding Advisory Committee; Notice of Meeting (April 16, 2026); National Cancer Institute, Hormone Therapy for Breast Cancer (updated September 2026), NCI Drug Dictionary entries for goserelin acetate, leuprolide acetate and nelipepimut-S plus GM-CSF vaccine, Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer and Cancer Treatment Vaccines; Breastcancer.org, 5 New Findings About GLP-1s and Breast Cancer (updated August 20, 2026); Harvard T.H. Chan School of Public Health, The Nutrition Source, Collagen (updated November 2024); NPR, FDA panel supports broadening access to peptides popular on the gray market (July 23, 2026); Associated Press, FDA panel narrowly backs peptide drug touted by influencers (July 24, 2026); Cavallaro and colleagues, Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics, Nanomaterials (September 2023); Huang and colleagues, The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects, Frontiers in Pharmacology (May 2023). This article is general information, written in Babette's own words, and is not a substitute for advice from your care team.
